Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by canadafanon Jan 02, 2023 3:17pm
279 Views
Post# 35199752

RE:1 year price target.

RE:1 year price target.Amazing anyone can post total none sense under the guise of professional analysts Tm
.
wtf is that?
i have read detailed analysts reports.
from the likes of RBC & 3-4:others.
All saying the same thing.
"speculative buy"..
one year target average about $8 usd .low of $6 high of $18
RBC has the lowest at $6 CDN with a caveat of $18 upside, should they form a partnership.
none of then discuss a buy- out as that is pure speculation.
they ALL base numbers on present value calculation of future sales possibilities of Pela.
That being from their estimates of potential cancer treatments etc. about $5 billion/ year in sales.
The difference becomes at what discount is used on the present value calculation , of potential future income.
look up on investopedia " how to value a biotech"
great read.

<< Previous
Bullboard Posts
Next >>